Payment overview · 2025
General Payments
$224.68
10 reported records · 7 companies
Healthcare provider profile · identity verified
Amanda Mccormick Willis, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · ALTOONA, AL · NPI 1508559956
Verified facts
What the public records show
CMS Open Payments records show Amanda Mccormick Willis, CRNP received $224.68 in general payments during 2025 across 10 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 31.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 10 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Gemtesa, Kerendia, Mounjaro, Ozempic, Rybelsus.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Kerendia by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 76 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $70.31 | 31.3% | 3 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $46.50 | 20.7% | 2 | 2025 |
| Atland Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $26.37 | 11.7% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $21.96 | 9.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $21.44 | 9.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $21.22 | 9.4% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.88 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $224.68 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $70.31 | 3 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $46.50 | 2 | 2025 |
Source payment records
|
|||||
| ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE Normalized: orphenadrine citrate aspirin and caffeine |
Drug | Atland Pharmaceuticals, LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| TOLMETIN SODIUM Normalized: tolmetin sodium |
Drug | Atland Pharmaceuticals, LLC | $26.37 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $21.96 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $21.44 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $21.22 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 76 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
32 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
76 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Omeprazole | Omeprazole | 284 | 91 |
| Levothyroxine Sodium | Levothyroxine Sodium | 267 | 80 |
| Lisinopril | Lisinopril | 242 | 96 |
| Pravastatin Sodium | Pravastatin Sodium | 225 | 63 |
| Metformin Hcl | Metformin Hcl | 170 | 59 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 152 | 58 |
| Atorvastatin Calcium | Atorvastatin Calcium | 152 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 150 | 61 |
| Escitalopram Oxalate | Escitalopram Oxalate | 144 | 39 |
| Fluticasone Propionate | Fluticasone Propionate | 137 | 72 |
| Losartan Potassium | Losartan Potassium | 125 | 53 |
| Montelukast Sodium | Montelukast Sodium | 123 | 39 |
| Buspirone Hcl | Buspirone Hcl | 120 | 38 |
| Pantoprazole Sodium | Pantoprazole Sodium | 118 | 54 |
| Eliquis | Apixaban | 100 | 22 |
| Furosemide | Furosemide | 98 | 38 |
| Trazodone Hcl | Trazodone Hcl | 97 | 36 |
| Farxiga | Dapagliflozin Propanediol | 96 | 27 |
| Metoprolol Succinate | Metoprolol Succinate | 90 | 36 |
| Fenofibrate | Fenofibrate | 86 | 34 |
| Carvedilol | Carvedilol | 83 | 35 |
| Mounjaro | Tirzepatide | 83 | 23 |
| Tamsulosin Hcl | Tamsulosin Hcl | 83 | 32 |
| Amitriptyline Hcl | Amitriptyline Hcl | 76 | 32 |
| Ozempic | Semaglutide | 76 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 75 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 69 | 15 |
| Quetiapine Fumarate | Quetiapine Fumarate | 69 | 25 |
| Citalopram Hbr | Citalopram Hydrobromide | 65 | 24 |
| Donepezil Hcl | Donepezil Hcl | 65 | 18 |
| Hydrochlorothiazide | Hydrochlorothiazide | 65 | 24 |
| Potassium Chloride | Potassium Chloride | 65 | 20 |
| Ondansetron Hcl | Ondansetron Hcl | 64 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 64 | 26 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 64 | 20 |
| Glipizide | Glipizide | 63 | 15 |
| Ondansetron Odt | Ondansetron | 63 | 36 |
| Ropinirole Hcl | Ropinirole Hcl | 63 | 26 |
| Meloxicam | Meloxicam | 61 | 25 |
| Simvastatin | Simvastatin | 58 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 57 | 22 |
| Glimepiride | Glimepiride | 56 | 16 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 56 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 55 | 20 |
| Fluconazole | Fluconazole | 54 | 37 |
| Clopidogrel | Clopidogrel Bisulfate | 53 | 19 |
| Memantine Hcl | Memantine Hcl | 52 | 12 |
| Sertraline Hcl | Sertraline Hcl | 52 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 49 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 22 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 48 | 11 |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 44 |
| Ezetimibe | Ezetimibe | 46 | 18 |
| Estradiol | Estradiol | 45 | 15 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 44 | 42 |
| Linzess | Linaclotide | 44 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 43 | 23 |
| Allopurinol | Allopurinol | 42 | 13 |
| Rexulti | Brexpiprazole | 41 | suppressed |
| Methocarbamol | Methocarbamol | 39 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 38 | 14 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 36 | suppressed |
| Nifedipine Er | Nifedipine | 36 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Methylprednisolone | Methylprednisolone | 35 | 32 |
| Topiramate | Topiramate | 35 | 14 |
| Meclizine Hcl | Meclizine Hcl | 34 | 12 |
| Nystatin | Nystatin | 34 | 22 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 33 | 12 |
| Gemtesa | Vibegron | 33 | suppressed |
| Famotidine | Famotidine | 32 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 32 | 13 |
| Trulicity | Dulaglutide | 32 | 11 |
| Cefdinir | Cefdinir | 30 | 29 |
| Azithromycin | Azithromycin | 29 | 29 |
| Bupropion Xl | Bupropion Hcl | 29 | suppressed |
| Repatha Sureclick | Evolocumab | 29 | suppressed |
| Celecoxib | Celecoxib | 27 | 13 |
| Spironolactone | Spironolactone | 27 | suppressed |
| Vascepa | Icosapent Ethyl | 27 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | 12 |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Atenolol | Atenolol | 22 | 14 |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 22 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 21 | suppressed |
| Ramipril | Ramipril | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Myrbetriq | Mirabegron | 19 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 18 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 17 | suppressed |
| Chlorthalidone | Chlorthalidone | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Primidone | Primidone | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 14 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Lamotrigine | Lamotrigine | 14 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 13 | suppressed |
| Finasteride | Finasteride | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Sucralfate | Sucralfate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | 11 |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 11 | suppressed |
| Lovastatin | Lovastatin | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Synthroid | Levothyroxine Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $224.68 · 10 records | Bayer Healthcare Pharmaceuticals Inc. | CAPLYTA, GEMTESA, Kerendia, MOUNJARO, ORPHENADRINE CITRATE, ASPIRIN AND CAFFEINE, OTEZLA, Ozempic, REPATHA, Rybelsus, TOLMETIN SODIUM | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Gemtesa play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Bayer Healthcare Pharmaceuticals Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error